| Patent application number | Description | Published |
|---|
| 20090082254 | Coupling of Polypeptides at the C-Terminus - The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications. | 03-26-2009 |
| 20090105134 | C-Terminally Pegylated Growth Hormones - Conjugated growth hormones of the structure (I) are provided together with methods for manufacturing said conjugates. The conjugates are useful in therapy. | 04-23-2009 |
| 20090149512 | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases - Ghrelin antagonists can be used for the treatment of certain CNS disorders. For example, certain oxadiazoles, preferably such being ghrelin antagonists, can be used to treat obesity, e.g., drug-induced obesity. | 06-11-2009 |
| 20090253166 | Conjugation of Peptides - Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group. | 10-08-2009 |
| 20090253864 | IL-21 Derivatives and Variants - The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules. | 10-08-2009 |
| 20090264435 | Novel Aryl- and Heteroarylpiperazines - Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor. | 10-22-2009 |
| 20100035814 | N-Terminal Pegylated Prolactin Receptor Molecules - The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants. | 02-11-2010 |
| 20100105617 | C-Terminal Attachment of Two Chemical Groups to Peptides - The present invention relates to a method for C-terminal attachment of two property-modifying groups to a peptide. | 04-29-2010 |
| 20100113747 | Coupling of Antibody Polypeptides at the C-Terminus - The present invention relates to a process for dimerization of antibody fragments, antibody fragment dimers, pharmaceutical compositions comprising antibody fragment dimers as well as their use in medicaments for therapeutic applications. The methods described can advantageously be used for producing bispecific antibodies and/or bispecific fragments thereof. | 05-06-2010 |
| 20100184641 | Novel Plasma Protein Affinity Tags - Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives. | 07-22-2010 |
